STOCK TITAN

DataMeds AI holders approve $1.36M note conversion

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
PRE 14C

Rhea-AI Filing Summary

DataMeds AI, Inc. (MEDS) reports that holders of a majority of its common stock approved by written consent dated October 19, 2026, the issuance of shares upon conversion of its note from Axe Compute Inc. The approval covers shares that, together with shares issued in the acquisition, may equal or exceed Nasdaq’s 20% issuance threshold. It becomes effective 20 calendar days after the information statement is first sent to stockholders.

The $1,363,672.00 note bears 7% simple annual interest and has an initial conversion price of $1.00 per share. At that price, principal alone converts into 1,363,672 shares. Unpaid interest may add shares unless DataMeds elects to pay it in cash; certain future below-price securities issuances may reduce the conversion price. The note automatically converts when the approval becomes effective.

The note was part of the consideration for DataMeds’ completed September 11, 2026 acquisition of all issued and outstanding shares of Helomics Corporation, alongside 636,328 DataMeds shares. The note is due September 11, 2029, at DataMeds’ election or upon demand by the holder, unless converted earlier.

Filing Explained

Axe’s listed 28.21% stake is a post-conversion figure, with 1,363,672 of its shares still unissued.

The written-consent approval is reported as obtained, but the note shares are not yet shown as issued; when the approval becomes effective, they automatically convert, increasing the share count and reducing existing holders’ percentage ownership, while Axe Compute’s reported 28.21% stake includes those shares.

As of October 31, 2026, the table lists 2,000,000 shares beneficially owned by Axe: 636,328 issued in the acquisition and 1,363,672 issuable on conversion; the 28.21% figure uses a denominator of 7,088,529 shares, including the conversion shares. The note also provides that a qualifying issuance below its current conversion price automatically reduces that price to the lower effective price, rather than using a weighted-average adjustment; the note lists exceptions.

Convertible note principal $1,363,672.00 Original principal amount of the note issued to Axe Compute Inc.
Interest rate 7% per annum Simple interest on the convertible note.
Initial conversion price $1.00 per share Subject to the note’s adjustment provisions.
Shares convertible from principal 1,363,672 shares At the initial conversion price, excluding shares for unpaid accrued interest.
Acquisition stock consideration 636,328 shares DataMeds common shares issued for the acquisition of Helomics Corporation.
Nasdaq issuance threshold 20% Approval was obtained because shares issued in connection with the acquisition and note conversion may equal or exceed this threshold of pre-issuance common stock or voting power.
Approval effectiveness period 20 calendar days After the information statement is first sent or given to stockholders.
Common shares outstanding 5,724,857 shares As of October 31, 2026.
Listing Rule 5635(a) regulatory
"for purposes of complying with Listing Rule 5635(a)"
Anti-Dilution Adjustment technical
"5.4 Anti-Dilution Adjustment"
Conversion Price financial
"the initial conversion price is $1.00 per share"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
general unsecured obligation financial
"This Note is a general unsecured obligation of the Company"
Senior Debt financial
"subordinated in right of payment to all current and future indebtedness"
Senior debt is borrowing that has first claim on a company's cash and assets if the company can't pay its bills, so lenders holding senior debt are repaid before other creditors and equity holders. Think of it as being first in line at a checkout; that priority makes senior debt lower risk and typically carries lower interest, and its size and terms matter to investors because they affect the safety of creditors and the potential upside or vulnerability of shareholders.
9.99% beneficial ownership limitation financial
"we refer to such provision as a “9.99% beneficial ownership limitation”"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MEDS shares could the Axe Compute note convert into?

At the initial $1.00 conversion price, the note’s $1,363,672.00 original principal converts into 1,363,672 shares. Unpaid accrued interest can add shares unless DataMeds elects to pay that interest in cash, and the note’s conversion-price adjustment provision can also increase the number of shares.

When does the DataMeds AI convertible note convert and mature?

The note’s principal and unpaid accrued interest automatically convert when stockholder approval becomes effective, 20 calendar days after the information statement is first sent or given to stockholders. Unless converted earlier, it is due September 11, 2029, at DataMeds’ election or upon demand by the holder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14C INFORMATION

 

Information Statement Pursuant to Section 14(c)

of the Securities Exchange Act of 1934 (Amendment No. _____)

 

Check the appropriate box:  
☒ Preliminary Information Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
☐ Definitive Information Statement

 

DATAMEDS AI, INC.
(Name of Registrant As Specified in Its Charter)

 

Payment of Filing Fee (Check all boxes that apply):
☒ No fee required
☐ Fee paid previously with preliminary materials.
☐ Fee computed on table in exhibit required by Item 25(b) of Schedule 14A per Item 1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11

 

 

 

 

 

 

DataMeds AI, Inc.

 

NOTICE OF STOCKHOLDER ACTIONS TAKEN BY WRITTEN CONSENT

 

To the Stockholders of DataMeds AI, Inc.:

 

This notice and the accompanying information statement are being furnished to the stockholders of DataMeds AI, Inc., a Delaware corporation (the “Company”), in connection with action taken by holders of a majority of the issued and outstanding shares of its common stock, approving, by written consent dated October 19, 2026 which is described in more detail in the accompanying information statement:

 

● for purposes of complying with Listing Rule 5635(a) of The Nasdaq Stock Market LLC, the issuance of shares of the Company’s common stock upon conversion of the convertible promissory note issued to Axe Compute Inc. on September 11, 2026 in the original principal amount of $1,363,672.00 (the “Convertible Note”), including shares issuable in respect of unpaid accrued interest and pursuant to adjustments to the conversion price, in excess of the applicable threshold set forth in Listing Rule 5635(a).

 

The purpose of this notice and accompanying information statement is to inform stockholders of record as of the close of business on __________, 2026, for informational purposes only, of stockholder approval of the actions described above. The accompanying information statement is first being mailed to stockholders on or about __________, 2026.

 

We Are Not Asking You for a Proxy and You Are Requested Not To Send Us a Proxy.

 

  By Order of the Board of Directors,
   
   
Tampa, Florida Prashant Patel
__________ , 2026 Co-Interim Chief Executive Officer & President

 

1

 

 

DataMeds AI, Inc.

3000 Bayport Drive, Suite 950

Tampa, FL 33607

 

INFORMATION STATEMENT

 

Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (the “Exchange Act”)

 

We Are Not Asking You for a Proxy and You are Requested Not To Send Us a Proxy

 

THIS INFORMATION STATEMENT IS INTENDED TO INFORM YOU OF THE ACTIONS APPROVED BY WRITTEN CONSENT OF A MAJORITY OF THE STOCKHOLDERS. WE ARE NOT REQUESTING YOUR VOTE OR SOLICITING YOUR PROXY.

 

This Information Statement is first being sent or given to stockholders on or about __________, 2026.

 

Introduction

 

This Information Statement is being furnished by DataMeds AI, Inc., a Delaware corporation (the “Company,” “DataMeds,” “we,” “us” or “our”), to its stockholders of record as of the close of business on __________, 2026, to inform such stockholders of actions taken by holders of a majority of the issued and outstanding shares of the Company’s common stock as of that date, approving, by written consent, for purposes of complying with Listing Rule 5635(a) of The Nasdaq Stock Market LLC, the issuance of shares of the Company’s common stock upon conversion of the convertible promissory note issued to Axe Compute Inc. on September 11, 2026 in the original principal amount of $1,363,672.00 (the “Convertible Note”), including shares issuable in respect of unpaid accrued interest and pursuant to adjustments to the conversion price, in excess of the applicable threshold set forth in Listing Rule 5635(a) (the “Corporate Action”), which is described in more detail in this Information Statement.

 

Stockholder Approval Obtained

 

Section 228 of the Delaware General Corporation Law (“DGCL”) provides that, unless otherwise provided in a corporation’s certificate of incorporation, any action required by the DGCL to be taken at any annual or special meeting of stockholders of a corporation, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation in the manner required by Section 228 of the DGCL.

 

Our bylaws provide that any action to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action to be so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to us.

 

Section 213(b) of the DGCL provides that, in order that a corporation may determine the stockholders entitled to consent to corporate action without a meeting in accordance with Section 228 of the DGCL, the board of directors may fix a record date. __________, 2026 was fixed as the record date for the foregoing purpose. As of __________, 2026, there were __________ shares of our common stock outstanding. Each holder of a share of our common stock is entitled to one vote for each share held by such holder.

 

Under rules of the U.S. Securities and Exchange Commission (the “SEC”), in the case of corporate actions taken by the consent of stockholders, the definitive information statement must be sent or given at least 20 calendar days prior to the earliest date on which the corporate actions approved by the consent of stockholders may be taken. Accordingly, the effectiveness of the stockholder approval of the matters described herein will be 20 calendar days after the date on which this Information Statement is first sent or given to the Company’s stockholders, or approximately __________, 2026.

 

2

 

 

No Appraisal Rights

 

Neither the DGCL nor our Amended and Restated Certificate of Incorporation provides our stockholders with appraisal rights in connection with the Corporate Action. This means that no stockholder is entitled to receive any cash or other payment as a result of, or in connection with, the Corporate Action, even if a stockholder has not been given an opportunity to vote.

 

Interest of Certain Persons in or Opposition to Matters to Be Acted Upon

 

Except with respect to the board designation rights described below and except to the extent of their ownership of shares of common stock, none of our directors or executive officers, any nominee for election as a director, or any associate of the foregoing persons has any substantial interest, direct or indirect, by security holdings or otherwise, in the Corporate Action.

 

Corporate Action

 

Action One: Approval of Share Issuances Upon Conversion of the Axe Compute Convertible Note

 

Our stockholders approved, for purposes of complying with Listing Rule 5635(a) of The Nasdaq Stock Market LLC, the issuance of shares of our common stock upon conversion of the Convertible Note, including shares issuable in respect of unpaid accrued interest and pursuant to adjustments to the conversion price, in excess of the applicable threshold set forth in Listing Rule 5635(a). Nasdaq Listing Rule 5635(a) requires stockholder approval prior to the issuance of securities in connection with the acquisition of the stock or assets of another company where, among other circumstances, the common stock to be issued or potentially issued equals or exceeds 20% of the common stock or voting power outstanding before the issuance.

 

On September 11, 2026, the Company entered into a stock purchase agreement with Axe Compute Inc. (“Axe”), pursuant to which the Company acquired all of the issued and outstanding shares of common stock of Helomics Corporation. The acquisition closed on September 11, 2026. The consideration consisted of 636,328 shares of the Company’s common stock, representing approximately 19.99% of the shares outstanding immediately prior to entry into the stock purchase agreement, and the Convertible Note in the original principal amount of $1,363,672.00.

 

The Convertible Note accrues simple interest at 7% per annum and, unless earlier converted, is due and payable on September 11, 2029, at the Company’s election or upon demand by the holder. Subject to receipt of stockholder approval, the holder may elect to convert the outstanding principal and unpaid accrued interest into shares of common stock prior to maturity. The outstanding principal and unpaid accrued interest automatically convert upon receipt of stockholder approval, subject to the effectiveness of that approval as described in this Information Statement. The Company may elect to pay unpaid accrued interest in cash at conversion.

 

The initial conversion price is $1.00 per share, subject to adjustment for stock splits, reverse stock splits, stock dividends, combinations, recapitalizations and similar events. At the initial conversion price, the original principal amount alone would convert into 1,363,672 shares of common stock. Additional shares may be issued in respect of unpaid accrued interest, unless paid in cash, and the number of shares issuable may increase if the conversion price is reduced.

 

The Convertible Note provides for an automatic reduction of the conversion price if, while the Convertible Note remains outstanding, the Company or any of its subsidiaries issues or sells, or is deemed to issue or sell, common stock or securities convertible into, exercisable for or exchangeable for common stock at an effective price below the then-current conversion price. Upon such an issuance, the conversion price is reduced to that lower effective price, rather than being adjusted on a weighted-average basis. For convertible or exercisable securities, the effective price is determined by dividing the aggregate consideration received or receivable for their issuance, plus the minimum additional consideration payable upon conversion, exercise or exchange, by the maximum number of common shares issuable under those securities. The reduced conversion price takes effect immediately and applies to all subsequent conversions of the Convertible Note.

 

Because the shares issuable upon conversion of the Convertible Note, considered together with the shares issued in connection with the acquisition, may equal or exceed 20% of the common stock or voting power outstanding before the issuance, stockholder approval is being obtained under Nasdaq Listing Rule 5635(a). The actual number of shares issued will depend on the outstanding principal, unpaid accrued interest, any election to pay interest in cash and the applicable conversion price at conversion.

 

The foregoing description of the Convertible Note is a summary and is qualified in its entirety by reference to the full text of the Convertible Note attached as Appendix A to this Information Statement.

 

3

 

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth certain information as of October 31, 2026, with respect to the holdings of each stockholder known by us to own beneficially more than 5% of the Company’s common stock, each of our directors and named executive officers, and all of our current directors and executive officers as a group. A person is deemed to be a beneficial owner of our common stock if that person has or shares voting power, which includes the power to vote or direct the voting of our common stock, or investment power, which includes the power to dispose of or to direct the disposition of our common stock. Except in cases where community property laws apply or as indicated in the footnotes to this table, we believe that each stockholder identified in the table possesses sole voting and investment power over all shares of the Company’s common stock shown as beneficially owned by the stockholder.

 

Name of Beneficial Owner(1)  Shares Beneficially Owned (Number)   Percent of Common Stock (%) 
Directors and Named Executive Officers          
Suren Ajjarapu(2)   456,532    7.97%
Prashant Patel(3)   419,805    7.33%
Shafaat Pirani   2,042    * 
Gary Herman   0    * 
Marlene Velez   0    * 
Donald Fell   0    * 
Eric Sherb   0    * 
All directors and executive officers as a group   878,379    15.34%
           
Other Five Percent Holders          
Annapurna Gundlapalli, Trustee of the Annapurna Gundlapalli Revocable Trust 2010   178,880    3.12%
Axe Compute Inc.(15)   2,000,000    28.21%
Data Health Partners, Inc.(16)   666,667    11.65%
Robert D. Keyser, Jr.(4)   635,389    9.99%
Sixth Borough Capital Fund, LP(5)   635,389    9.99%
Robert Forster(6)   635,389    9.99%
Cory Wachowitz(7)   467,772    7.55%
Robert D. Keyser, III(8)   467,772    7.55%
Mehmet Gunay(9)   635,389    9.99%
Dominic Linsalata(10)   269,995    4.50%
Sandip Patel(11)   635,389    9.99%
Ault Lending LLC(12)   570,940    9.07%
Esousa Holdings LLC(13)   635,389    9.99%
Jess Mogul(14)   635,389    9.99%

 

*Represents beneficial ownership of less than 1%

 

(1) The mailing address of all individuals listed is c/o DataMeds AI, Inc., 3000 Bayport Drive, Suite 950, Tampa, FL 33607.

 

(2) Includes (i) 257,645 shares owned directly by Mr. Ajjarapu, (ii) 89,264 shares owned by the Sandhya Ajjarapu Revocable Trust 2007, for which Mr. Ajjarapu claims beneficial ownership through his wife, Sandhya Ajjarapu, who serves as trustee, (iii) 62,000 shares owned by Sansur Associates LLC, an entity that Mr. Ajjarapu beneficially owns and for which Mr. Ajjarapu thereby claims beneficial ownership, and (iv) 47,326 shares owned by Sea Rider Capital LLC, an entity that Mr. Ajjarapu beneficially owned.

 

4

 

 

(3) Includes (i) 282,365 shares owned directly by Mr. Patel, (ii) 89,440 shares owned by the Patel Trust 2010, for which Mr. Patel claims beneficial ownership, as co-trustee with his wife, Rina Patel, and (iii) 48,000 shares owned by Goldshield Health LLC, an entity that Mr. Patel beneficially owns and for which Mr. Patel thereby claims beneficial ownership.

 

(4) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder. The convertible notes and warrants held by this stockholder have a provision that prohibits the stockholder from converting such notes and/or exercising such warrants to the extent that doing so would result in the beneficial ownership of this stockholder exceeding 9.99% (we refer to such provision as a “9.99% beneficial ownership limitation”). The number of shares shown in the table for this stockholder give effect to the 9.99% beneficial ownership limitation.

 

(5) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(6) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(7) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(8) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(9) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(10) Includes 3,082 shares of common stock underlying convertible notes and 33,712 shares of common stock underlying a warrant to purchase common stock held by this stockholder.

 

(11) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(12) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(13) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(14) Includes shares issuable upon conversion of convertible notes and/or exercise of warrants held by this stockholder, in each case giving effect to the 9.99% beneficial ownership limitation.

 

(15) Consists of (i) 636,328 shares issued to Axe Compute Inc. as a portion of the consideration under the Stock Purchase Agreement dated September 11, 2026 pursuant to which the Company acquired Helomics Corporation, as described under “Action One” above, and (ii) 1,363,672 shares issuable upon conversion of the Convertible Note at the initial conversion price of $1.00 per share. The Convertible Note converts upon effectiveness of the stockholder approval described under “Action One,” which the Company expects to occur within 60 days of the date of the table above. The percentage shown is calculated on 7,088,529 shares, consisting of the 5,724,857 shares outstanding as of October 31, 2026 plus the 1,363,672 shares issuable upon conversion of the Convertible Note. Additional shares may become issuable in respect of unpaid accrued interest or upon adjustment of the conversion price. Axe Compute Inc. is a reporting company whose common stock is listed on The Nasdaq Stock Market under the symbol “AGPU.”

 

(16) Consists of (i) 295,567 shares held directly by Data Health Partners, Inc. and (ii) 371,100 shares held by REBOOT Health AI, Inc., a wholly owned subsidiary of Data Health Partners, Inc., over which Data Health Partners, Inc. may be deemed to exercise voting and dispositive power. The shares were issued in connection with the exclusive license, revenue sharing and marketing agreement entered into with REBOOT Health AI, Inc. in October 2026.

 

5

 

 

Householding of Materials

 

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy delivery requirements for information statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single set of materials addressed to those stockholders. This process, which is commonly referred to as householding, potentially provides extra convenience for stockholders and cost savings for companies.

 

If you are a stockholder of record and share an address with another stockholder and have received multiple copies of our materials and wish to receive a single copy in the future, or if you only received a single copy and wish to receive a separate copy of the materials, you may write or call us at our address and phone number reported elsewhere in this document. We undertake to deliver promptly upon written or oral request a separate copy of the materials, as requested, to a stockholder at a shared address to which a single copy of the materials was delivered.

 

If your stock is held through a brokerage firm or bank and you prefer to receive separate copies of our materials either now or in the future, please contact your brokerage firm or bank.

 

Additional Information

 

Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, and proxy statements and other information we file or furnish pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website at www.datamedsai.com under the Investors tab as soon as reasonably practicable after we electronically file such reports with, or furnish them to, the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including our company.

 

Other Matters

 

THIS INFORMATION STATEMENT IS DATED __________, 2026. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS INFORMATION STATEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THAT DATE, AND THE MAILING OF THIS INFORMATION STATEMENT TO STOCKHOLDERS DOES NOT CREATE ANY IMPLICATION TO THE CONTRARY. You should rely only on the information provided in this Information Statement. We have not authorized any person to provide information other than that provided herein.

 

We will pay all costs associated with the distribution of this Information Statement, including the costs of printing and mailing. We will reimburse brokerage firms and other custodians, nominees and fiduciaries for reasonable expenses incurred by them in sending this Information Statement to the beneficial owners of our common stock.

 

Our address and phone number is DataMeds AI, Inc., 3000 Bayport Drive, Suite 950, Tampa, FL 33607, Attn: Corporate Secretary, 1-843-302-1785.

 

6

 

 

APPENDIX A

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF

 

CONVERTIBLE PROMISSORY NOTE

 

$1,363,672.00 Date of Issuance: September 11, 2026

 

FOR VALUE RECEIVED, DataMeds AI, Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of Axe Compute Inc. (the “Holder”), the principal sum of $1,363,672.00, together with interest thereon from the date of this Note. Interest will accrue at a simple rate of seven percent (7%) per annum. Unless earlier converted into Conversion Shares pursuant to the terms hereof, the principal and accrued interest of this Note will be due and payable by the Company on September 11, 2029 (the “Maturity Date”) at the Company’s election or upon demand by the Holder.

 

This Note (this “Note”) is issued by the Company to Holder pursuant to that certain Stock Purchase Agreement entered into as of the date of issuance of this Note between the Company and Holder (the “Purchase Agreement”). Certain capitalized terms not defined herein will have the meanings set forth in the Purchase Agreement.

 

1. Payment. All payments will be made in lawful money of the United States of America at the principal office of the Company, or at such other place as the Holder may from time to time designate in writing to the Company. Payment will be credited first to accrued interest due and payable, with any remainder applied to principal.

 

2. Prepayment. This Note may be prepaid at any time before the Maturity Date without any penalties.

 

3. Security. This Note is a general unsecured obligation of the Company.

 

 

 

 

4. Priority. This Note is subordinated in right of payment to all current and future indebtedness of the Company for borrowed money (whether or not such indebtedness is secured) to banks, commercial finance lenders or other institutions regularly engaged in the business of lending money (the “Senior Debt”). The Company hereby agrees, and by accepting this Note, the Holder hereby acknowledges and agrees, that so long as any Senior Debt is outstanding, upon notice from the holders of such Senior Debt (the “Senior Creditors”) to the Company that an event of default, or any event which the giving of notice or the passage of time or both would constitute an event of default, has occurred under the terms of the Senior Debt (a “Default Notice”), the Company will not make, and the Holder will not receive or retain, any payment under this Note. Nothing in this paragraph will preclude or prohibit the Holder from receiving and retaining any payment hereunder unless and until the Holder has received a Default Notice (which will be effective until waived in writing by the Senior Creditors) or from converting this Note or any amounts due hereunder into Conversion Shares pursuant to the terms hereof.

 

5. Conversion of this Note.

 

5.1 Optional Conversion. Subject to the receipt of Stockholder Approval, the Holder may elect at any time prior to the Maturity Date, by written notice to the Company, to convert the outstanding principal balance and unpaid accrued interest on this Note, subject to the terms and conditions contained herein, into Conversion Shares.

 

5.2 Automatic Conversion. The principal balance and unpaid accrued interest on this Note shall automatically convert into Conversion Shares upon receipt of Stockholder Approval.

 

5.3 Mechanics of Conversion.

 

(a) Payment of Interest. Notwithstanding the foregoing, upon the conversion of this Note, the Company may, at its sole option, elect to pay any unpaid accrued interest on this Note in cash at the time of conversion.

 

(b) Conversion Shares. The number of Conversion Shares to be issued upon the conversion of this Note shall be equal to the quotient obtained by dividing (A) the outstanding principal and unpaid accrued interest on this Note (unless the Company elects to repay the interest portion), on the date of conversion, by (B) the applicable Conversion Price.

 

(c) Termination of Rights. Except for the right to obtain certificates representing the Conversion Shares pursuant to this Note or payment for a fractional share as set forth herein, all rights with respect to this Note shall terminate upon the effective conversion of the entire balance of this Note as provided herein whether or not this Note is surrendered to the Company. Notwithstanding the foregoing, the Holder agrees to surrender this Note to the Company (or lost note documentation in the form prescribed by the Company (the “Lost Note Documentation”), where applicable) as soon as practicable after conversion. In any event, the Holder shall not be entitled to receive any stock certificates representing the Conversion Shares issuable upon conversion of this Note unless and until the Holder has surrendered the original of this Note (or Lost Note Documentation where applicable) and the applicable documentation (as provided for above).

 

(d) Certificates. As promptly as practicable after the conversion of this Note and the issuance of the Conversion Shares, the Company (at its expense) will issue and deliver to the Holder a certificate or certificates evidencing the Conversion Shares (if certificated), or if the Conversion Shares are not certificated, will deliver a true and correct copy of the Company’s share register reflecting the Conversion Shares held by the Holder.

 

(e) No Voting or Other Rights. This Note does not entitle the Holder to any voting rights or other rights as a stockholder of the Company, unless and until (and only to the extent that) this Note is actually converted into Conversion Shares in accordance with its terms. In the absence of conversion of this Note into Conversion Shares, no provisions of this Note, and no enumeration herein of the rights or privileges of the Holder, shall cause the Holder to be a stockholder of the Company for any purpose.

 

2

 

 

(f) No Fractional Conversion Shares. If the conversion of this Note would result in the issuance of a fractional Conversion Share, the Company shall, in lieu of issuance of any fractional share, round up such fractional share to the next whole share.

 

5.4 Anti-Dilution Adjustment. If, at any time while this Note is outstanding, the Company or any of its subsidiaries issues or sells, or is deemed to have issued or sold (as provided below), any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock (collectively, “New Securities”) at an effective price per share that is less than the Conversion Price then in effect (such price, the “Dilutive Issuance Price”), then immediately upon such issuance or sale (or deemed issuance or sale), the Conversion Price shall automatically be reduced to the Dilutive Issuance Price. For purposes of this provision, the effective price per share of any New Securities that are convertible into or exercisable or exchangeable for shares of Common Stock shall be determined by dividing (x) the aggregate consideration received or receivable by the Company for the issuance or sale of such New Securities, plus the minimum aggregate amount of additional consideration, if any, payable upon conversion, exercise or exchange thereof, by (y) the total maximum number of shares of Common Stock issuable upon conversion, exercise or exchange of such New Securities. Any modification, amendment, repricing, cancellation and reissuance, or other change to the terms of any outstanding options, warrants, convertible securities, or other rights to acquire Common Stock that has the effect of reducing the exercise price, conversion price, or other price at which shares of Common Stock may be acquired shall be deemed to be a new issuance of such securities at such reduced price as of the date of such modification, amendment, repricing, cancellation and reissuance, or other change. Notwithstanding the foregoing, this provision shall not apply to (i) shares of Common Stock issued or issuable upon conversion of this Note, (ii) shares of Common Stock issued or issuable as a dividend or distribution on, or upon a stock split, subdivision or combination of, the outstanding shares of Common Stock (which adjustments are governed by the definition of Conversion Price set forth herein), (iii) shares of Common Stock or options or warrants to purchase shares of Common Stock issued or issuable to employees, officers, directors or consultants of the Company pursuant to any equity incentive plan or agreement approved by the Company’s board of directors, or (iv) shares of Common Stock issued or issuable in connection with any bona fide arm’s-length acquisition by the Company of any business, assets or securities of another entity that is not an affiliate of the Company, approved by a majority of the disinterested members of the Company’s board of directors.. Any adjustment to the Conversion Price pursuant to this provision shall be effective immediately upon the issuance or sale (or deemed issuance or sale) of such New Securities and shall apply to all subsequent conversions of this Note.

 

6. Restrictions on Transfer. The Holder acknowledges that it has been advised by the Company that this Note has not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), that the Note is being issued, on the basis of the statutory exemption provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder relating to transactions by an issuer not involving any public offering, and that the Company’s reliance upon this statutory exemption is based in part upon the representations made by the Holder in the Purchase Agreement. The Holder acknowledges that it has been informed by the Company of, or is otherwise familiar with, the nature of the limitations imposed by the Securities Act and the rules and regulations thereunder on the transfer of securities. In particular, the Holder agrees that no sale, assignment, hypothecation or transfer of this Note shall be valid or effective, and the Company shall not be required to give any effect to any such sale, assignment, hypothecation, transfer or other disposition, unless (i) the sale, assignment, hypothecation, transfer or other disposition of this Note is registered under the Securities Act, provided, that the Company has no obligation or intention to so register this Note in connection herewith, or (ii) this Note is sold, assigned, hypothecated, transferred or otherwise disposed of in accordance with all the requirements and limitations of Rule 144 under the Securities Act, or such sale, assignment, or transfer is otherwise exempt from registration under the Securities Act.

 

3

 

 

7. Definitions.

 

7.1 “Common Stock” means shares of common stock of the Company, par value $0.0001 per share.

 

7.2 “Conversion Price” means $1.00, as adjusted pursuant to Section 5.4 and from time to time for any stock splits, reverse stock splits, stock dividends, combinations, recapitalizations or other similar events affecting the outstanding shares of Common Stock (each, an “Adjustment Event”). In the event of any Adjustment Event, the Conversion Price shall be proportionately adjusted so that the Holder shall be entitled to receive, upon conversion of this Note, the same number of Conversion Shares that the Holder would have been entitled to receive had the conversion occurred immediately prior to such Adjustment Event.

 

7.3 “Conversion Shares” means shares of Common Stock.

 

7.4 “Stockholder Approval” means the approval by the stockholders of the Company, at a duly called and held meeting of stockholders (or by written consent in lieu thereof), of the issuance of the Conversion Shares upon conversion of this Note, to the extent required by Nasdaq Listing Rule 5635(a) or any successor rule thereto.

 

8. Amendments and Waivers. Any term of this Note may be amended and the observance of any term of this Note may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Holder.

 

9. Choice of Law and Jurisdiction. This Note shall be governed by the laws of the State of Delaware as applied to contracts entered into and to be performed entirely within the State of Delaware. Any action arising out of this Note shall be brought exclusively in a court of competent jurisdiction in New Castle County, Delaware, and the parties hereby irrevocably waive any objections they may have to venue in New Castle County, Delaware.

 

10. Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS NOTE, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER REPRESENTS AND WARRANTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

11. Notice. Any notice, request or other communication required or permitted hereunder shall be in writing and shall be deemed to have been duly given if personally delivered or mailed by registered or certified mail, postage prepaid, or delivered by electronic transmission, to the Company at the address set forth in the Purchase Agreement or to the Holder at its address set forth in the Purchase Agreement. Any party hereto may by notice so given change its address for future notice hereunder. Notice shall conclusively be deemed to have been given when personally delivered or when deposited in the mail in the manner set forth above and shall be deemed to have been received when delivered or, if notice is given by electronic transmission, when delivered with confirmation of receipt.

 

4

 

 

12. Successors and Assigns. Any transfer of this Note may be effected only pursuant to the terms hereof and by surrender of this Note to the Company and reissuance of a new note to the transferee. The Holder and any subsequent holder of this Note receives this Note subject to the foregoing terms and conditions, and agrees to comply with the foregoing terms and conditions for the benefit of the Company.

 

13. Officers and Directors not Liable. In no event will any officer or director of the Company be liable for any amounts due and payable pursuant to this Note.

 

14. Limitation on Interest. In no event will any interest charged, collected or reserved under this Note exceed the maximum rate then permitted by applicable law, and if any payment made by the Company under this Note exceeds such maximum rate, then such excess sum will be credited by the Holder as a payment of principal. For avoidance of doubt, other than in an Event of Default, in no event will interest be required to be paid under this Note until the Maturity Date (pursuant to the terms set forth herein) or upon the conversion of this Note to shares of the Company pursuant to the terms hereof.

 

15. Transfer of this Note. Subject to the transfer restrictions set forth herein, this Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Assuming compliance with the previous sentence, this Note shall be reissued to, and registered in the name of, the transferee, or a new note for like principal amount and interest shall be issued to, and registered in the name of, the transferee. Interest and principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company’s obligation to pay such interest and principal.

 

16. Events of Default. If there shall be any Event of Default (as defined below) hereunder, at the option and upon the declaration of the Holder and upon written notice from the Holder to the Company (which election and notice shall not be required in the case of an Event of Default under subsections (ii) or (iii) below), this Note shall accelerate, and all principal and unpaid accrued interest shall become due and payable. The occurrence of any one or more of the following shall constitute an “Event of Default”:

 

(i) the Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and payable or any unpaid accrued interest or other amounts due under this Note on the date the same becomes due and payable;

 

(ii) the Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; or

 

(iii) an involuntary petition is filed against the Company (unless such petition is dismissed or discharged within sixty (60) days under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee or assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company).

 

17. Company Waiver; Delays and Omissions. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. It is agreed that no delay or omission to exercise any right, power or remedy accruing to the Holder, upon any breach or default of the Company under this Note shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.

 

18. Severability. If one or more provisions of this Note are held to be unenforceable under applicable law, then such provision(s) shall be excluded from this Note to the extent they are held to be unenforceable and the remainder of the Note shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms.

 

[Remainder of Page Intentionally Left Blank]

 

5

 

 

  DATAMEDS AI, INC.
     
  By:              
  Name:   
  Title:  

 

 

 

Keep reading